Browsing by Author "Baris, Serap Argun"

Filter results by typing the first few letters
Now showing 1 - 2 of 2
  • Thumbnail Image
    Item
    The association of antiviral drugs with COVID-19 morbidity: The retrospective analysis of a nationwide COVID-19 cohort
    (FRONTIERS MEDIA SA, 2022-01-01) Babayigit, Cenk; Kokturk, Nurdan; Kul, Seval; Cetinkaya, Pelin Duru; Nayci, Sibel Atis; Baris, Serap Argun; Karcioglu, Oguz; Aysert, Pinar; Irmak, Ilim; Yuksel, Aycan Akbas; Sekibag, Yonca; Toprak, Oya Baydar; Azak, Emel; Mulamahmutoglu, Sait; Cuhadaroglu, Caglar; Demirel, Aslihan; Kerget, Bugra; Ketencioglu, Burcu Baran; Ozger, Hasan Selcuk; Ozkan, Gulcihan; Ture, Zeynep; Ergan, Begum; Oguz, Vildan Avkan; Kilinc, Oguz; Ercelik, Merve; Ciftci, Tansu Ulukavak; Alici, Ozlem; Temel, Esra Nurlu; Ataoglu, Ozlem; Aydin, Asena; Bahcetepe, Dilek Cetiner; Gullu, Yusuf Taha; Fakili, Fusun; Deveci, Figen; Kose, Neslihan; Tor, Muge Meltem; Gunluoglu, Gulsah; Altin, Sedat; Turgut, Teyfik; Tuna, Tibel; Ozturk, Onder; Dikensoy, Oner; Gulhan, Pinar Yildiz; Basyigit, Ilknur; Boyaci, Hasim; Oguzulgen, Ipek Kivilcim; Borekci, Sermin; Gemicioglu, Bilun; Bayraktar, Firat; Elbek, Osman; Hanta, Ismail; Kuzu Okur, Hacer; Sagcan, Gulseren; Uzun, Oguz; Akgun, Metin; Altinisik, Goksel; Dursun, Berna; Edis, Ebru Cakir; Gulhan, Erkmen; Eyuboglu, Fusun Oner; Gultekin, Okkes; Havlucu, Yavuz; Ozkan, Metin; Coskun, Aysin; Sayiner, Abdullah; Kalyoncu, A. Fuat; Itil, Oya; Bayram, Hasan
    Background and objectivesAlthough several repurposed antiviral drugs have been used for the treatment of COVID-19, only a few such as remdesivir and molnupiravir have shown promising effects. The objectives of our study were to investigate the association of repurposed antiviral drugs with COVID-19 morbidity. MethodsPatients admitted to 26 different hospitals located in 16 different provinces between March 11-July 18, 2020, were enrolled. Case definition was based on WHO criteria. Patients were managed according to the guidelines by Scientific Board of Ministry of Health of Turkey. Primary outcomes were length of hospitalization, intensive care unit (ICU) requirement, and intubation. ResultsWe retrospectively evaluated 1,472 COVID-19 adult patients
  • Thumbnail Image
    Item
    The predictors of COVID-19 mortality in a nationwide cohort of Turkish patients
    (W B SAUNDERS CO LTD, 2021-01-01) Kokturk, Nurdan; Babayigit, Cenk; Kul, Seval; Cetinkaya, Pelin Duru; Nayci, Sibel Atis; Baris, Serap Argun; Karcioglu, Oguz; Aysert, Pinar; Irmak, Ilim; Yuksel, Aycan Akbas; Sekibag, Yonca; Toprak, Oya Baydar; Azak, Emel; Mulamahmutoglu, Sait; Cuhadaroglu, Caglar; Demirel, Aslihan; Kerget, Bugra; Ketencioglu, Burcu Baran; Ozger, Hasan Selcuk; Ozkan, Gulcihan; Ture, Zeynep; Ergan, Begum; Oguz, Vildan Avkan; Kilinc, Oguz; Ercelik, Merve; Ciftci, Tansu Ulukavak; Alici, Ozlem; Temel, Esra Nurlu; Ataoglu, Ozlem; Aydin, Asena; Bahcetepe, Dilek Cetiner; Gullu, Yusuf Taha; Fakili, Fusun; Deveci, Figen; Kose, Neslihan; Tor, Muge Meltem; Gunluoglu, Gulsah; Altin, Sedat; Turgut, Teyfik; Tuna, Tibel; Ozturk, Onder; Dikensoy, Oner; Gulhan, Pinar Yildiz; Basyigit, Ilknur; Boyaci, Hasim; Oguzulgen, I. Kivilcim; Borekci, Sermin; Gemicioglu, Bilun; Bayraktar, Firat; Elbek, Osman; Hanta, Ismail; Okur, Hacer Kuzu; Sagcan, Gulseren; Uzun, Oguz; Akgun, Metin; Altinisik, Goksel; Dursun, Berna; Edis, Ebru Cakir; Gulhan, Erkmen; Eyuboglu, Fusun Oner; Gultekin, Okkes; Havlucu, Yavuz; Ozkan, Metin; Coskun, Aysin Sakar; Sayiner, Abdullah; Kalyoncu, Ali Fuat; Itil, Oya; Bayram, Hasan
    The COVID-19-related death rate varies between countries and is affected by various risk factors. This multi-center registry study was designed to evaluate the mortality rate and the related risk factors in Turkey. We retrospectively evaluated 1500 adults with COVID-19 from 26 centers who were hospitalized between March 11 and July 31, 2020. In the study group, 1041 and 459 cases were diagnosed as definite and highly probable cases, respectively. There were 993 PCR-positive cases (66.2\%). Among all cases, 1144 (76.3\%) were diagnosed with non-severe pneumonia, whereas 212 (14.1\%) had severe pneumonia. Death occurred in 67 patients, corresponding to a mortality rate of 4.5\% (95\% CI:3.5-5.6). The univariate analysis demonstrated that various factors, including male sex, age >= 65 years and the presence of dyspnea or confusion, malignity, chronic obstructive lung disease, interstitial lung disease, immunosuppressive conditions, severe pneumonia, multiorgan dysfunction, and sepsis, were positively associated with mortality. Favipiravir, hydroxychloroquine and azithromycin were not associated with survival. Following multivariate analysis, male sex, severe pneumonia, multiorgan dysfunction, malignancy, sepsis and interstitial lung diseases were found to be independent risk factors for mortality. Among the biomarkers, procalcitonin levels on the 3rd-5th days of admission showed the strongest associations with mortality (OR: 6.18